Please assess the completion status of the following clinical trial:

Trial Title: RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \>=1 measurable disease site per RECIST, not previously irradiated (if previous radiation to marker lesion(s), need evidence of PD)~* Histologic dx of well- to moderately-differentiated NET: low- or intermediate-grade, islet cell carcinoma, pancreatic NET, carcinoid, atypical carcinoid, paraganglioma, pheochromocytoma. No longer enrolling carcinoid patients as of 4/25/2011.~* ≥4 wks since completion of prior investigational drug tx or other tx(radiation, chemotherapy, immunotherapy, antibody-based tx); recovery from acute toxicities of prior tx~* Eastern Cooperative Oncology Group (ECOG) ≤2~* Absolute Neutrophil Count (ANC) ≥1500/μL~* Plts ≥100,000/μL~* Hgb \>9 gm/dL~* Total bilirubin ≤2.0 mg/dL or 1.5X upper limit of normal (ULN)~* Serum transaminases ≤2.5x ULN (≤5xULN if liver mets)~* Serum Cr ≤2.0 mg/dL or 1.5X ULN~* Fasting serum glucose \<150 mg/dL or \<1.5x ULN~* Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤2.5xULN~* International Normalized Ratio (INR) ≤1.5~* Written informed consent, compliance w/study requirements~* Archived tissue if available~* Negative urine/serum pregnancy test w/in 7 days prior to Day 1~Exclusion Criteria:~* Poorly differentiated NET, high-grade NET, adenocarcinoid, goblet cell carcinoid, small cell carcinoma~* Major surgery or traumatic injury w/in 4 wks, inadequate recovery from side effects of any surgery, or likely to require major surgery during study~* Liver-directed therapy w/in 2 mths of enrollment. Prior tx w/ radiotherapy (including radiolabeled spheres, cyberknife, hepatic arterial embolization (w/ or w/o chemotherapy), cryotherapy/ablation) allowed if areas of measurable disease being used for the study are not affected, or if PD can clearly be documented in the area~* Prior tx w/ EGFR inhibitor or mTOR inhibitor~* Known hypersensitivity to RAD001 or other rapamycins~* Chronic, systemic tx w/ corticosteroids or another immunosuppressive agent (topical or inhaled corticosteroids are allowed)~* Immunization w/ attenuated live vaccines w/in 1 wk of study entry or during study~* Uncontrolled brain or leptomeningeal mets, including pts who continue to require glucocorticoids for brain or leptomeningeal mets~* Other malignancies w/in the past 3 years except for adequately treated carcinoma of the cervix, basal/squamous cell skin carcinomas, or other in situ cancer~* Severe and/or uncontrolled intercurrent medical conditions or other conditions that may affect study participation, including, but not limited to:~* Severely impaired lung function (spirometry and Diffusing capacity of the lungs for carbon monoxide (DLCO) that is 50% of the normal predicted value and/or O2 saturation ≤88% at rest on room air)~* Symptomatic congestive heart failure (CHF) of New York Heart Association (NYHA) Class III or IV~* Unstable angina pectoris, symptomatic CHF, myocardial infarction w/in 6 months of Day 1, uncontrolled cardiac arrhythmia or any other significant cardiac disease~* Uncontrolled diabetes (fasting serum glucose ≥ 150 mg/dL or \>1.5x upper limit of normal (ULN))~* Any active (acute or chronic) or severe infection, disorder, or nonmalignant medical illness that is uncontrolled or whose control may be jeopardized by study tx~* Liver disease~* Hx of HIV seropositivity or other immunocompromised state~* GI function impairment or disease that may alter absorption of RAD001 or erlotinib~* Active, bleeding diathesis or on oral anti-vitamin K medication (patients needing anticoagulation must use low molecular weight heparin (LMWH))~* Hx of other disease, metabolic dysfunction, or physical exam or lab finding giving reasonable suspicion of disease/condition that contraindicates study tx, might affect study results or puts the pt at high risk~* Pregnant or breast feeding females~* Adults of reproductive potential not willing to use effective methods of birth control during tx and ≥8 wks after completing tx~* Inability to comply w/ objectives and procedures~* Inability to comply w/ concomitant medication restrictions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAD001 and erlotinib (Type: EXPERIMENTAL): Each 28 day cycle:~RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues